A B S T R A C T To delineate the extent to which bone marrow transplantation provides "enzyme replacement therapy", we have determined metabolite concentrations in two patients with adenosine deaminase (ADA) deficiency treated with bone marrow transplants and rendered immunologically normal. 10 yr after engraftment of lymphoid cells, erythrocyte deoxy ATP was markedly decreased compared to the marked elevations of deoxy ATP observed in untreated patients, but was still significantly elevated (62 and 90 vs. normal of6.0+6.0 nmol/ml packed erythrocytes). Similarly, deoxyadenosine and adenosine excretion were both markedly diminished compared to that of untreated patients but deoxyadenosine excretion was still clearly increased (20.1 and 38.6 vs. normal of <0.2 nmol/mg creatinine) while adenosine excretion was in the upper range of normal (7.0 and 8.1 vs. normal of 5.6+3.6 nmol/mg creatinine). Mononuclear cell deoxy ATP content was also elevated compared to normal (5.25 and 14.4 vs. 1.2+0.3). Separated mononuclear cells of bone marrow transplanted patients contain both donor lymphocytes and recipient monocytes. When mononuclear cells were depleted of the patients' own monocytes, the deoxy ATP content of the cells enriched for donor lymphocytes (i.e. monocyte depleted) was lower than that of the mixed mononuclear cells (2.2 vs. 5.26). Surprisingly, plasma adenosine was as high as in untreated ADA-deficient patients (3.2 and 1.5 vs. untreated of 0.3-3 ,uM). Consistent with the elevated plasma adenosine and Portions of this work were presented in part at the 92nd Annual Meeting ofthe Association ofAmerican Physicians and was published in abstract form in
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Children with ADA-SCID can be returned to normal immunologic function by transplantation of bone marrow from a related histocompatible donor. The ease of engraftment and subsequent immunologic reconstitution of ADA-deficient patients has not differed appreciably from that of non-ADA-deficient SCID, although cells other than lymphoid cells remain ADA-deficient (18) .
Immunologic reconstitution following bone marrow transplantation is generally presumed to result from I Abbreviations used in this paper: ADA, adenosine deaminase; DCF, deoxycoformycin; HPLC, high pressure liquid chromatography; PCA, perchloric acid; SAH hydrolase, S-adenosyl homocysteine hydrolase; SCID, severe combined immunodeficiency. Urinary nucleosides. Urine (stored frozen at -70°C with 0.01% azide) was defrosted, warmed briefly and a 3-ml aliquot removed, diluted to 10 ml with H2O, brought to pH 10.0 and chromatographed on an anion exchange column (Bio-Rad, AG 1-X2) as described by Kuttesch et al. (10) . The fraction containing adenosine was lyophilized, reconstituted with H2O and analyzed by "reverse phase" high-pressure liquid chromatography (HPLC) as previously described (9) using a C18 ,uBondapack Column and a 0-40% linear gradient of 0.01 M ammonium phosphate (pH 5.5) and methanol, generated over 60 min with a 1.5 ml/min flow rate. Adenosine and deoxyadenosine were identified by retention times, coelution with the authentic compounds, disappearance after incubation with exogenous ADA (0.12 IU/ml for 2 h at 370C), the appearance of, or increase in a peak with the retention time of inosine and/or deoxyinosine and the 250/260 UV ratios of the substrates and products. Uric acid and creatinine were determined in the diluted and undiluted urine.
Erythrocyte and mononuclear cell dATP. Erythrocyte dATP was determined as previously described (9) using a DNA polymerase-dependent assay based upon the method of Solter and Handschumacher (21) . The erythrocytes were extracted with perchloric acid (PCA) and freon/amine (22 (23) , used dADP and dAMP as well as dATP in a polymerase assay.
PCA extraction of the methanol extract eliminated utilization of the mono-and dinucleotides. Recovery experiments indicated that a 5 min extraction with PCA followed by extraction with freon/amine resulted in -80-90% recovery of added dATP while reducing utilization of dADP to <10% of methanol extracts. Longer extractions with PCA resulted in poorer recoveries. Cells were therefore extracted and assayed for dATP content essentially by this slight modification of the method of North et al. (23) using a shorter time for PCA extraction. In brief, the cell pellet was resuspended in 1 ml 60% methanol, vortexing vigorously for 1-3 min at 4°C and kept at -20°C for 36 h. After centrifugation in a Beckman microfuge, the methanol extract was removed, brought to dryness under a stream of nitrogen, resuspended in 100 ,l H20 and immediately extracted with 50 ,ul 2.1 N PCA for 5 min at 4°C and then extracted with freon/amine (22) . The extract was again brought to dryness, resuspended in 30 gl of H20 and assayed for dATP content using poly dA-dT as described by North et al. (23) and Escherichia coli DNA polymerase. The extracts did not significantly utilize dADP or dAMP and there was a linear increase in dATP with increasing extract volume in the assay, extrapolating to a "blank" identical with the reagent blank.
Determination of total deoxyadenosine containing compounds in mononuclear cells was performed based on the method described by Hershfield et al. (24) . Mononuclear cells were prepared as described above, the cell pellet frozen at -70°C and then directly extracted with PCA-freon/amine (22) . To 180 ,ul of neutralized extract was added 40 ul of 0.5 M Tris buffer, pH 8.0, containing 20 ,uM erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), and 10 ul of bovine intestinal alkaline phosphatase containing 1 U (type VII S-Sigma Co.). The mixture was incubated for 1 h at 37°C and the reaction terminated by addition of 40 gl 2.1 N PCA and neutralized with 40 ul 2.21 N KOH. The supernatant was then analyzed for deoxyadenosine by HPLC on a C18 gBondapak column (9) . Preliminary experiments indicated that under these conditions, dAMP, dADP and dATP were totally converted to deoxyadenosine, but that no other reaction products were seen. The sensitivity was such that 10 pmol of deoxyadenosine could easily be detected in the presence of 50,000 pmol of adenosine. In analysis of cell extracts, the identity of the peak eluting with the retention time of deoxyadenosine was confirmed by collecting the peak, drying under nitrogen, incubating with calf intestinal ADA and determining the amount of deoxyinosine (as identified by retention time and 250/260 ratios) generated.
Plasma nucleosides. Plasma adenosine and deoxyadenosine were determined as described (9) . In brief, immediately after venepuncture, plasma was rapidly separated from whole blood by centrifuging in a Beckman microfuge at 4°C for 1-2 min and an equal volume of cold methanol was immediately added to the plasma. (25) . The areas migrating with AMP and ATP, hypoxanthine and inosine and adenosine, were then counted in a Beckman liquid scintillation counter. All other areas of the chromatogram were also counted and contained c2% of the total radioactivity.
S-adenosyl homocysteine (SAH) hydrolase activity. SAH hydrolase activity of erythrocytes was measured by determining the rate of synthesis of SAH from adenosine and homocysteine (20 analyzed for SAH content by HPLC using the gradient system described for analysis of adenosine and deoxyadenosine. The reaction was linear in time and for varying concentrations of lysate. SAH eluted before adenosine with a retention time relative to adenosine of 0.86. Adenine, inosine, AMP, and hypoxanthine had relative retention times of 0.7, 0.5, 0.4 and 0.3, respectively.
Patients. The case histories ofboth patients to age five and their erythrocyte ADA activity have been previously reported (18) . They are currently both 10 yr of age. All tests of immune functions are normal, as is their height, weight, and development. The patients' erythrocytes remain their own and are ADA-deficient, whereas both B and T lymphocytes are of donor origin and contain ADA. Monocytes would appear to have remained of recipient origin, as determined by the analysis for Y bodies in patient 1. Mononuclear cell ADA (i.e. mixed lymphocytes and monocytes) of patient 1 is 194 nmol/mg protein per h, while that of his female sibling bone marrow donor is 424 nmol/mg protein per h. Normal mononuclear cell ADA by this method is 665+154 (n = 14) (24).
RESULTS
Erythrocyte dATP. Erythrocytes from both bone marrow transplanted patients contained increased dATP compared with normal (Table I) . However, the erythrocyte dATP content of the bone marrow transplanted, ADA-deficient patients was markedly lower than that found in erythrocytes of untreated, ADAdeficient patients (500-1,000 nmol/ml packed erythrocytes) (7, 8, 11) . The heterozygous sibling bone marrow donor for patient 1 had erythrocyte dATP within the normal range (data not shown).
Mononuclear cell dATP. dATP content of mononuclear cells (mixed lymphocytes and monocytes) was also found to be increased compared with normals (5.4 and 14.4 vs. Urinary adenosine and deoxyadenosine. Both bone marrow transplanted children still excreted easily detectable concentrations of deoxyadenosine, (Table  II) , albeit <10% of that excreted by untreated ADAdeficient patients (300-1,000 nmol/mg creatinine) (6, 10, 11) . Normal children excrete <0.2 nmol deoxyadenosine/mg creatinine. Both patients excreted concentrations of adenosine in the upper range of normal. These concentrations of adenosine were, however, lower than the concentrations of adenosine excreted by untreated patients (24-31 nmol/mg creatinine) (10, 11). Similar results were obtained if the results were expressed relative to uric acid excretion (Table II) .
Plasma adenosine and deoxyadenosine. Deoxyadenosine, which we have found in micromolar concentration in plasma of untreated ADA-deficient patients (9), could not be detected in the plasma of either of the bone marrow transplanted patients (<0.2 ,M). In contrast, plasma adenosine was in the micromolar range, as high as that found in plasma of untreated or erythrocyte transfused patients (4, 7, 9, 12) (Table II) . Because the marked elevation of plasma adenosine was not consistent with the only minimal elevations of other metabolites, we considered the possibility that this apparent increase in plasma adenosine might in a sense be "artifactual". Thus, in vivo, plasma adenosine presumably represents an equilibrium state between purines produced and excreted by cells with active de novo purine biosynthetic pathways (such as hepatocytes) and uptake and metabolism by cells such as erythrocytes that have only a "salvage pathway" for purines. Plasma adenosine, once removed from the body and a continuing source of renewal, could still be rapidly taken up and metabolized by the normal red cells containing ADA, even in the brief interval required for separation ofplasma from erythrocytes. Since erythrocytes of the bone marrow transplanted patients still lack ADA and are incapable of deaminating adenosine during processing, the ex vivo concentration ofadenosine might more closely approximate the in vivo concentration in ADA-deficient patients than in normals. In order to mimic the conditions present in ADA-deficient patients, we withdrew venous blood from normals into a syringe containing DCF, a potent inhibitor of ADA. We found that adenosine in plasma obtained from two normal individuals without addition of DCF was 0.026 and 0.032 ,uM. When the blood was drawn into a syringe containing DCF (final concentration of 1-2 uM) then plasma adenosine of three normal individuals was 10 times higher (0.28, 0.33 and 0.32 ,uM). However, in preliminary experiments, even in the presence ofthese high concentrations of DCF, we found that we could not recover -80% of adenosine added to whole blood when adenosine content of the separated plasma was determined by HPLC. This "loss" was not due to metabolism following separation of plasma from erythrocytes, since 87-110% of adenosine added to separated plasma could be recovered as adenosine (data not shown). To determine if the 80% of the added adenosine "lost" from plasma had been deaminated, even in the presence of high concentrations of DCF, we added freshly drawn, heparinised blood to radiolabeled adenosine and DCF (final concentrations of 1 MuM adenosine and 1 or 2 MuM DCF, separated the plasma from erythrocytes, extracted both and determined the distribution of radiolabel as determined by chromatography on DE81 paper (25) . The majority of the added adenosine (Table III) was taken up into the erythrocytes and three-fourths of the intra-erythrocytic radioactivity was present as phosphorylated compounds (50-70% of total label) while approximately one-fifth had been metabolized to inosine and hypoxanthine (15. 8-22% of total) and only a small percentage remained as adenosine. The plasma contained 8-13% of the total radioactivity, of which -60% was present as adenosine. The combined conversion of -20% of the total adenosine to inosine and hypoxanthine, in the presence of high concentrations ofthe potent ADA inhibitor DCF, could represent either (a) less efficient and/or less rapid uptake of DCF than of adenosine into erythrocytes and therefore incomplete inhibition of ADA in erythrocytes; (b) the activity of an additional serum aminohydrolase present in plasma of ADA-deficient children as well as normals that is less inhibitable by DCF (28) or (c) further metabolism of AMP to IMP to inosine and then hypoxanthine by the sequential action of AMP deaminase, 5'-nucleotidase, and nucleoside phosphorylase. Of these possibilities, less rapid uptake of DCF by intact erythrocytes and incomplete inhibition of ADA did not appear to play a significant role, since neither preincubation of blood with DCF for 20 min before addition of the radiolabeled adenosine nor doubling the concentrations of DCF had any significant effect on the percentage of adenosine converted to hypoxanthine and inosine. Our ability to quantitatively recover adenosine added to separated plasma suggests that the serum adenosine aminohydrolase activity does not play a significant role and that the radiolabeled inosine and hypoxanthine in plasma probably derived from intra-erythrocytic metabolismii by the pathway suggested above. All of these findings indicate that in the presence of DCF, the major route of metabolism of adenosine during processing of whole blood is by pathways not affected in ADA-deficient blood, i.e. by rapid uptake into erythrocytes with phosphorylation (29, 30) and subsequent metabolism of a proportion of the phosphorylated compounds to inosine and hypoxanthine via AMP deaminase, 5'-nucleotidase, and nucleoside phosphorylase. Additionally, we have found, in an ADA-deficient child in whom all erythrocytes had been replaced by ADA normal erythrocytes, that plasma adenosine concentration remained elevated at 1 and 2 ,uM. Thus the presence of ADA normal erythrocytes was not sufficient to lower ex vivo plasma adenosine during processing even to the higher values observed in normal plasma when whole blood was processed in the presence of DCF. Finally, even if the hypoxanthine and inosine, which was produced from adenosine in the presence of DCF, reflects incomplete inhibition of ADA, this would account for only a 20% lowering of normal plasma adenosine during processing. Therefore, the concentrations of adenosine in plasma of the bone marrow transplanted ADA-deficient patients appear to be truly higher than that observed in normals, even with addition of DCF (1 and 3 vs. 0.3 ,uM) and in the range of untreated or exchange-transfused ADA-deficient patients.
SAH hydrolase. It has been reported that deoxvadenosine irreversibly inactivates the enzyme SAH hydrolase in vitro (3) and erythrocytes from untreated ADA-deficient patients do show markedly diminished SAH hydrolase activity (16). If adenosine and/or deoxyadenosine concentrations were increased in vivo in the bone marrow transplanted patients, we would expect to find a secondary inactivation of the enzyme SAH hydrolase. SAH hydrolase activity was diminished in erythrocytes of the bone marrow transplanted patients, but not in those of the sibling donor (Table IV) . Using a more sensitive enzymatic assay, we now find that erythrocyte dATP is still clearly greater than normal in these two patients, albeit <10% of the dATP concentrations found in untreated ADA-deficient patients. We also find that deoxyadenosine is excreted in increased amounts and that plasma adenosine is in the same range as that seen in untreated patients. In contrast, plasma deoxyadenosine could not be detected. SAH hydrolase activity is also diminished in erythrocytes of our bone marrow transplanted patients, consistent with increased plasma adenosine and urinary deoxyadenosine. Deoxy ATP and "total deoxyadenosine" content of the mononuclear cells also appears to be slightly elevated. However, when the mononuclear cells are depleted of monocytes, the dATP content of the lymphocytes (which are of donor origin and contain ADA) is lower than that of the monocytes (which do not appear to be of donor origin) and approaches the normal range. The observations reported here raise several questions. First, our results suggest that in vivo concentration of plasma adenosine in both normals and ADAdeficient patients may be considerably greater than those determined by conventional techniques. Ultrarapid sampling and separation techniques may allow for the determination ofthe absolute in vivo concentration of adenosine in both normal and ADA-deficient human plasma. Such studies would have bearing on evaluating the physiologic significance of the reported multiple effects of adenosine. Nonetheless, the plasma concentration of adenosine in bone marrow-transplanted patients does appear to be increased relative to normal as in untreated patients. The finding of elevated plasma adenosine in the bone marrowtransplanted patients in the face of normal immunological function, suggests that an action of adenosine at a cell surface lymphocyte adenosine receptor does not play a significant role in the pathophysiology of the immunodeficiency.
The studies reported indicate that lymphoid cell engraftment provides marked but not complete clearing of abnormal metabolites from nonlymphoid body compartments of ADA-deficient patients. The concentrations of metabolites reported here may provide a "bench mark" against which to monitor the appropriate dosage and biochemical efficacy of alternate therapies under study, such as exchange transfusions (12) , in patients for whom no bone marrow donor is available.
